H. Jiang et al. have recently showed that OX40L-armed Onc.Ad (Delta-24-RGDOX) has a stronger anticancer efficacy compared to its predecessor Delta-24-RGD, triggering a greater tumor-specific lymphocyte activation and a proliferation of TAAs-specific CD8+ T-cells in two mouse glioma models [60]. Here, CD8A is linked to glioma.